Connection

BRYAN K KEE to CD8-Positive T-Lymphocytes

This is a "connection" page, showing publications BRYAN K KEE has written about CD8-Positive T-Lymphocytes.
Connection Strength

0.032
  1. Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer. Cancer Immunol Res. 2023 07 05; 11(7):925-945.
    View in: PubMed
    Score: 0.032
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.